Overview of Barios

Property	Description
Active ingredient	Nebivolol
Form	Tablet (oral dosage form)
Pharmacological class	beta-Adrenergic receptor blocker (third-generation)
General Purpose	Cardiovascular workload reduction
Origin	Synthetic

Barios is a prescription-only medication classified as a third-generation beta-adrenergic receptor blocker (beta-blocker), whose primary function is to support cardiovascular health by moderating the heart's activity and promoting the widening of blood vessels. The medicine is a synthetic compound supplied as an oral dosage form, specifically a tablet, intended for oral route administration. Its identity is defined by its single active ingredient, Nebivolol, which is recognized for its profile within its class.

What Type of Medicine is Barios?

Barios is formally categorized as a third-generation beta-adrenergic receptor blocker, a class that achieves highly cardioselective beta1-blockade. This classification describes the medicine’s inherent selectivity for the beta1 receptors found predominantly in the heart. Unlike many older beta-blockers, Nebivolol is distinguished by its additional capacity to promote vasodilation, making it a dual-action agent that addresses both cardiac rate and vascular resistance. This property allows the medicine to modulate heart activity while also helping to ease resistance in the blood vessels.

Composition and The Unique Action of Nebivolol

The active ingredient of Barios is Nebivolol, which is prepared as a racemic mixture containing two distinct chemical forms known as enantiomers—the D- and L-forms. The presence of these two enantiomers is central to its function, as they each contribute a specific physiological action: the D-form is primarily responsible for the cardioselective action, while the L-form facilitates endothelial function modulation. This latter action involves stimulating the release of nitric oxide (NO) within the blood vessel lining, which induces vasodilation (vessel widening). This dual mechanism is a primary differentiating factor for Nebivolol compared to less selective agents.

What is the General Purpose of This Drug Class?

The general purpose of Barios is to decrease the overall workload on the cardiovascular system through its combined cardioselective beta1-blockade and vasodilation mechanisms. By reducing the heart's rate and force of contraction, the energy demand of the heart is lessened. Concurrently, the reduction of resistance in the peripheral blood vessels facilitates easier blood flow. This dual action serves the fundamental therapeutic purpose of supporting regulated circulation within the body.

Regulatory References

What side effects are possible with Barios?

Possible Side Effects and Safety Information

The safety profile for Barios, which contains the active ingredient Nebivolol, is officially documented and classified by regulatory authorities based on the frequency and system-organ class affected by adverse reactions. This classification framework defines the expected safety characteristics of the medicine.

Frequency-Classified Adverse Reactions

The official labeling organizes possible side effects into categories reflecting their typical incidence:

Common (1/100 to < 1/10): Reactions frequently documented include headache, dizziness, fatigue, oedema, constipation, nausea, and diarrhea.
Uncommon (1/1,000 to < 1/100): Less frequent documented effects involve bradycardia (slowed heart rate), heart failure aggravation, hypotension, depression, and bronchospasm.
Rare to Very Rare: Serious or less frequent reactions, such as syncope (fainting), angioedema, jaundice, or severe dermatological conditions like Stevens-Johnson syndrome, are documented in the rare or very rare classifications.

Serious Adverse Reactions and Key Safety Constraints

Certain reactions, while often rare, carry significant clinical weight and are highlighted in regulatory documents. These include aggravation of existing heart failure, severe bradycardia, and syncope. The official label also notes the potential for severe hypersensitivity reactions.

Regarding treatment patterns, regulatory safety information explicitly states that abrupt discontinuation of this therapy should be avoided due to the associated risk of exacerbating existing cardiac conditions or inducing acute cardiovascular events. Furthermore, caution is required when the medicine is used in individuals with hepatic impairment or severe renal failure, or in those with certain pre-existing conditions such as bronchospastic diseases, as detailed in the official prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information is based on official government regulatory documents detailing the known risks and required actions in case of an overdose with Barios.

Documented Overdose Manifestations

An overdose with Barios, particularly when combined with other CNS depressants, may lead to serious and life-threatening clinical signs. The documented manifestations include:

Central Nervous System Depression: Profound sleepiness (somnolence), stupor, confusion, or coma.
Respiratory Depression: Severely slowed, shallow, or ceased breathing, which is the primary cause of life-threatening outcome.
Other Physical Signs: Pinpoint pupils (miosis), flaccid muscles, and low blood pressure (hypotension).

Immediate Emergency Action

Urgent medical attention is required immediately if an overdose is suspected or if the affected person exhibits severely slowed breathing, unresponsiveness, or collapse.

Always call 9-1-1 (or local emergency services) without delay.

If an approved opioid antagonist (such as naloxone) is available, it should be administered immediately while awaiting emergency medical personnel. Patients must be monitored continuously for a return of respiratory depression, as the effects of the reversal agent may wear off before the effects of Barios, potentially requiring repeated antagonist doses and prolonged observation in a clinical setting. Overdose management is primarily supportive, focusing on maintaining ventilation and a patent airway.

Therapeutic Uses of Barios

Barios is commonly used in therapeutic domains involving certain distressing symptoms related to the cardiovascular system. The medication is primarily applied in addressing essential hypertension (high blood pressure) and stable chronic heart failure in elderly patients. The medication is applied across therapeutic domains where additional symptomatic support is needed, consistent with official guidelines.

Use and Supportive Benefit

Barios is relevant for conditions characterized by periods of heightened symptoms and is generally applied in settings where additional symptomatic support is needed. It plays a role in managing symptoms related to systemic imbalance that create noticeable physiological strain. The core benefit is that this therapy may assist with reducing the long-term probability of serious cardiovascular events, while also providing support that eases the overall symptom burden in stable heart failure patients. The medicine is also relevant for managing angina pectoris (chest discomfort) and is considered relevant for patients with co-occurring factors like diabetes.

“This therapy may support the patient by easing distress and assists with maintaining functional stability in long-term chronic conditions.”

Quick Fact: Relevant for managing Elevated Blood Pressure and Exertional Chest Discomfort

Clinical Scenarios

The medicine is applied in scenarios where symptoms link to organ-specific functional stress. It supports general well-being during symptomatic phases and is frequently used as a foundational treatment for adults with mild to moderate persistent pressure elevation, as well as an additive therapy for older adults managing chronic cardiac dysfunction.

Regulatory References

FDA Verification Portal (Philippine FDA) on Nebivolol Indications

Eligibility and Restrictions for Use

Who Can and Cannot Use Barios?

Eligibility for Barios (Nebivolol) is strictly determined by official regulatory documentation, which outlines approved populations and absolute contraindications.

Populations with Absolute Contraindications

Barios is officially prohibited for use in individuals with specific, severe pre-existing conditions. These include:

Severe Bradycardia (severely slow heart rate)
Second or Third-Degree Heart Block
Cardiogenic Shock or Decompensated Cardiac Failure
Severe Hepatic Impairment (Child-Pugh Class C)
Hypersensitivity to Nebivolol or any product component

Age and Organ Function Eligibility

Category	Regulatory Status
Pediatric Use (le 18 years)	Not Recommended. Safety and effectiveness have not been established.
Adult Use (ge 18 years)	Approved and Established for hypertension.
Older Adults (ge 70 years)	Established for stable chronic heart failure.
Severe Renal Impairment	Restricted Use. Use is not established in patients on dialysis.

Pregnancy and Lactation

Use during pregnancy is restricted to situations where the potential benefit justifies the risk to the fetus. Use during lactation is generally not recommended due to potential risk to the infant, as stated in regulatory labels.

What should I know about interactions with other medicines?

Barios Interactions with other medicines and products

This section details documented interaction information for Barios (Nebivolol) as established in official government regulatory documents.

Interaction Type	Interacting Substances/Categories	Regulatory Description
Exposure Modification (PK)	CYP2D6 Enzyme Inhibitors (e.g., Fluoxetine, Paroxetine), Cimetidine	Co-administration is documented to substantially increase the plasma concentration of the active drug component.
Pharmacodynamic (PD)	Calcium Channel Blockers (Verapamil, Diltiazem-type), Digitalis Glycosides, Class I/III Antiarrhythmics	Additive effects are officially noted, leading to the risk of excessive reductions in heart rate, conduction, and blood pressure.
Absorption Interference (PK)	Antacids (Aluminum Hydroxide-containing)	Documented to reduce drug absorption when taken simultaneously.

Population and Condition Restrictions

The use of Barios is formally contraindicated in patients with severe hepatic impairment (Child-Pugh >B) due to significantly reduced drug clearance. Furthermore, individuals identified as CYP2D6 Poor Metabolizers are noted in regulatory documents as having substantially higher systemic exposure to the drug.

Interaction-Related Constraints

Official regulatory texts identify certain combinations, such as with Class I Antiarrhythmics or Centrally Acting Antihypertensives (e.g., Clonidine), as generally not recommended or subject to sequencing rules. Administration of Barios and antacids requires a separation of at least 2 hours to mitigate interference with absorption.

Mechanism of Action

Selective Cardiac Signal Dampening

Barios functions as a selective antagonist (blocker) primarily targeting Beta-1 adrenergic receptors in the cardiac tissue. By preventing the binding of activating chemical messengers, this action decreases the demand for oxygen consumption by the cardiac muscle. This results in a slowing of the heart rate (negative chronotropy) and a decrease in the force of contraction (negative inotropy).

Nitric Oxide-Mediated Vessel Relaxation

Barios also engages a complementary mechanism that promotes the release of the signaling molecule nitric oxide ( NO) from the inner lining of blood vessels (endothelium). NO acts on the adjacent vascular smooth muscle, signaling them to relax, which leads to the widening of blood vessels (vasodilation).

Dual Modulation of Circulation Dynamics

The drug’s dual mechanism combines reduced cardiac output (from Beta-1 blockade) and decreased peripheral resistance (from NO-mediated vasodilation). This synergistic effect leads to a decrease in the pressure exerted on the circulatory system, resulting in a coordinated modulation of the variables governing blood flow.

Dosage and Administration Information

Barios is administered exclusively via the oral route as a tablet. The medicine is intended for once-daily use, and the schedule for administration is consistent regardless of food intake. The core principle of initiating therapy involves a two-phase process: a slow starting dose followed by a careful adjustment period called titration, which varies based on the condition being addressed.

For essential hypertension, the official starting dosage is typically 5 mg once daily, and dosage increases may be made at intervals of approximately two weeks. In the management of stable chronic heart failure, treatment begins at a lower initial dose of 1.25 mg once daily. This dose is subsequently doubled at weekly or bi-weekly intervals until the maximum tolerated daily dose, generally 10 mg, is achieved. The initiation of chronic heart failure therapy requires observation under specialized medical supervision for a period of at least two hours to ensure stability.

Usage instructions include specific rules for certain populations. Patients with severe kidney or moderate liver impairment require a starting dose reduction to 2.5 mg daily, followed by slow titration. If a dose is missed, the standard procedure is to skip the dose if it is close to the time for the next scheduled dose, and never take a double dose. Barios is intended for long-term therapy, and the entire course of treatment must conclude with a gradual decrease (tapering) over a one- to two-week period, as abrupt cessation is restricted by official protocol.

Recent Clinical Evidence

Research evidence / Overview of studies for Barios

Evidence from Trials for Essential Hypertension

Research for essential hypertension (high blood pressure) primarily used short-term, randomized, double-blind, placebo-controlled trials (RCTs). These studies examined the change in Sitting Systolic and Diastolic Blood Pressure (SBP/DBP) in adults with mild to moderate high blood pressure. Trials also explored measurements related to the body's vascular function and examined Barios alongside other high blood pressure medicines.

The short-term RCTs reported measurements of patterns in blood pressure compared to the readings observed when participants were given an inactive substance. Other research explored the association between Barios and systemic or functional imbalance by monitoring measurements like endothelial function and arterial stiffness.

Evidence from Trials for Stable Chronic Heart Failure

The main evidence base supporting use in stable chronic heart failure comes from one large-scale, multi-center, Randomized, Placebo-Controlled Outcomes Trial. This research was specifically evaluated in a population of older adults aged 70 years and above who had stable, long-term heart failure. The large trial monitored for a composite endpoint of all-cause mortality or hospital admission due to cardiovascular issues.

Findings described patterns observed in the studies related to the time until the first event occurred. Observations were generally consistent across the study cohort, which included patients with both reduced and preserved left ventricular function.

Focus of Long-Term Studies and Follow-up

Most hypertension trials featured limited follow-up durations (e.g., a few weeks). Data for the long-term, sustained measurements of Barios in relation to reducing cardiovascular events are primarily extrapolated from the known benefits of controlling blood pressure, rather than being established by dedicated, long-term Barios trials. For heart failure, the primary outcomes trial was of intermediate duration, with patients monitored for about 21 months on average, which provided data on longer-term outcomes.

Research in Special Populations

Barios was evaluated in populations including specific analyses for older adults in the hypertension trials, as well as those with co-occurring conditions like diabetes. The largest research involving a special population was the heart failure trial, centered on older adults aged 70 years and above. Conversely, comparative evidence and dedicated trials are limited for pediatric populations, pregnant individuals, and very old or highly medically complex adults.

What the Regulatory Research Landscape Shows

The evidence landscape includes randomized controlled trials (RCTs) for both approved indications, but limitations still exist. Research provides context but not individual predictions; findings describe group patterns, not personal outcomes. Key limitations include the fact that most hypertension trials featured limited follow-up durations. For heart failure, the evidence was centered on the older adult population, meaning that results apply most directly to the populations studied, and data for other groups remain insufficient.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Barios (FAQ)

Q: How does Barios compare to other similar medicines in the same class?

Official drug classifications describe Barios (Nebivolol) as a third-generation beta-adrenergic receptor blocker. Its profile is considered unique within its class due to its documented dual mechanism. This involves highly cardioselective beta1-blockade (moderating heart activity) combined with a complementary action that promotes the widening of blood vessels (vasodilation).

Q: Can Barios make existing health issues, like high blood pressure, worse?

Official safety documents caution that Barios may mask certain symptoms of low blood sugar in patients with diabetes or symptoms of hyperthyroidism. The label also advises caution in individuals with certain chronic obstructive pulmonary diseases (COPD) or bronchospastic diseases, as this medication could potentially worsen breathing difficulty.

Q: What is the official information regarding Barios and liver function?

Barios is formally contraindicated for use in individuals with severe hepatic (liver) impairment, which means it is prohibited in these cases. Patients documented with moderate hepatic impairment are noted in official prescribing information as requiring a reduced starting dose.

Q: Does Barios have a warning about driving or operating machinery?

Official documents describe adverse reactions such as dizziness, fatigue, and syncope (fainting), which are effects that may impact a person's alertness and coordination. Regulatory guidance notes that patients should be aware of how the medicine affects them before operating vehicles or complex machinery.

Q: Is there a patient brochure or a medication guide for Barios I can read?

Regulatory authorities require that official patient information, such as a Medication Guide or Patient Information Leaflet, be made available for prescription medicines. This guide provides a summary of the approved uses, safety information, and basic administration instructions.

Q: Is Barios a controlled substance or addictive?

Barios (Nebivolol) is a prescription-only medication and belongs to the beta-adrenergic receptor blocker class. It is not classified as a controlled substance by major government drug enforcement bodies, and it is not documented in official sources as having addiction potential.

Q: Can I take Barios with over-the-counter pain relievers like ibuprofen or acetaminophen?

Official drug interaction information notes that combining beta-blockers with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which include common pain relievers like ibuprofen, may reduce the medicine's effectiveness in lowering blood pressure. Acetaminophen is not specifically noted in this interaction.

Q: Does Barios interact with alcohol or caffeine?

Documented information states that alcohol (ethanol) may have an additive effect with Barios in lowering blood pressure. This may lead to an increased risk of adverse reactions such as headache, dizziness, lightheadedness, or fainting.

Q: Are there any specific foods or drinks to avoid while using Barios?

Regulatory documents state that Barios can be taken without regard to food intake. However, official interaction information notes that Antacids require a separation of at least two hours to mitigate interference with drug absorption.

Q: Is Barios approved for use in children or adolescents?

Barios (Nebivolol) is not approved for use in children or adolescents (individuals ages le 18 years). Regulatory documentation explicitly states that the safety and effectiveness of the medicine in this pediatric population have not been established.

Q: What is the current official recommendation for Barios use during pregnancy?

Use during pregnancy is restricted to situations where the potential benefit is determined to justify the risk to the fetus. Official information notes that beta-blockers used during the third trimester are associated with risks such as slow heart rate, low blood pressure, and low blood sugar in the newborn after delivery.

Q: If Barios is working, how will I know?

Regulatory guidance advises patients taking Barios to monitor their blood pressure and heart rate regularly. The medicine works to reduce the heart rate and lower blood pressure, which are key physiological measurements. These measurements are key indicators related to the drug’s intended activity.

Q: What if I'm not feeling better after the time my doctor said I should?

Regulatory documents state that dosage adjustments for blood pressure control can be made at intervals of approximately two weeks and that blood pressure should be monitored regularly until it is controlled. Official guidelines describe that if an adequate response is not achieved, the treatment plan may be adjusted, which can include dose increases or the addition of other medicines.

Q: Is Barios a new drug, or has it been used for a while?

Barios (Nebivolol) was patented in 1983 and was first approved for medical use in certain international markets in 1997. It received regulatory approval for use in the United States in the mid-2000s, indicating it has been in use globally for several decades.

Q: How is Barios different from a supplement or natural remedy?

Barios is defined in regulatory documents as a synthetic, prescription-only medication belonging to the beta-adrenergic receptor blocker class. This means it is subjected to strict government standards for approval that ensure quality, safety, and evidence-based efficacy, standards that do not apply to over-the-counter supplements.

Q: Can Barios affect my sleep patterns?

Official safety information classifies insomnia (sleeplessness) and nightmares as uncommon adverse reactions that have been documented with Barios use. These effects relate to the central nervous system.

Q: Do I need to get blood tests while I am using Barios?

The official label does not mandate routine blood tests for all patients. However, the medicine requires caution in patients with severe kidney or moderate liver issues. Individuals with pre-existing conditions like diabetes may require specific blood monitoring to track their health status.

Q: What should I do if a side effect is bothering me but is not listed as serious?

Regulatory guidance indicates that patients should consult with their healthcare provider if they experience adverse reactions. Official product information notes that certain mild side effects may change as the body adjusts, and they are typically monitored or addressed under professional supervision.

Q: Will Barios affect my ability to breastfeed?

Use during lactation is generally not recommended in official documents due to the potential for adverse effects in the breastfed infant. These potential effects include slow heart rate (bradycardia), respiratory distress, and low blood sugar (hypoglycemia).

Q: Is there a link between Barios and changes in vision?

Official safety information lists impaired vision as an uncommon adverse reaction that has been documented with Barios use. Documented adverse reactions, such as changes in vision, are usually reviewed and assessed by a healthcare provider.

Q: How long does Barios stay in the body after the last dose?

The half-life of the active component of Barios (Nebivolol) is officially documented as approximately 10 hours for most individuals. However, the half-life is noted to be substantially longer (about 30 hours) in individuals who are documented as having slower drug metabolism.

Q: Is Barios used to prevent a condition or just to manage symptoms?

Barios is approved for the management of essential hypertension (high blood pressure) and stable chronic heart failure. Official research for heart failure studied a composite endpoint related to cardiovascular events and hospital admission, which focuses on managing the progression and symptoms of the condition.

Q: Is there a higher chance of side effects for certain people using Barios?

Official documents note that individuals classified as 'CYP2D6 Poor Metabolizers' have substantially higher systemic exposure to the drug compared to others. This means the drug may stay in their system longer and at higher levels, which may increase the chance of experiencing side effects.

How should Barios be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define the storage and disposal for BARIOS (Nebivolol) tablets.

Requirement Area	Regulatory Condition
Storage Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Container Protection	The medicine must be dispensed in a tight, light-resistant container.
Child Safety	Keep out of the sight and reach of children.
Disposal	Do not dispose of BARIOS in the wastewater (sink or toilet). Discard unused product via a drug take-back program.

Storage within the controlled temperature range and protection from light and moisture are mandatory to maintain product quality. The required use of a child-resistant closure and storing the medicine out of a child’s reach are specified handling requirements. Disposal must align with pharmaceutical waste rules, strictly prohibiting flushing the tablets into the sanitary sewer system.

Barios